Skip to main content
Allogene Therapeutics, Inc. logo

Allogene Therapeutics, Inc. — Investor Relations & Filings

Ticker · ALLO ISIN · US0197701065 US Manufacturing
Open in API
Filings indexed 523 across all filing types
Latest filing 2019-03-15 Director's Dealing
Country US United States of America
Listing US ALLO

About Allogene Therapeutics, Inc.

https://allogene.com/

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies. The company engineers T cells from healthy donors to create "off-the-shelf" treatments for cancer and autoimmune diseases. This approach is designed to enable on-demand availability, scalability, and reliability, contrasting with autologous therapies that use a patient's own cells. Allogene's pipeline utilizes multiplex gene-engineering and gene-editing capabilities. Its key investigational programs include cemacabtagene ansegedleucel (cema-cel) for large B-cell lymphoma, ALLO-316 for clear cell renal cell carcinoma, and ALLO-329 for autoimmune disease.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2019-03-15 English
FORM 4 SUBMISSION
Director's Dealing
2019-03-15 English
FORM 4 SUBMISSION
Director's Dealing
2019-03-15 English
S-8
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as stock option plans or employee stock purchase plans. The text includes details about the Amended and Restated 2018 Equity Incentive Plan and the 2018 Employee Stock Purchase Plan, including the number of shares registered and the registration fee calculation. It also references incorporation by reference of prior filings and includes signatures of officers and board members. This type of filing is related to share issuance under employee plans and is not a financial report, earnings release, or management discussion. It is specifically a registration statement for securities issuance under employee benefit plans, which corresponds to a Share Issue/Capital Change announcement rather than a full report or other categories. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length and content confirm it is not a brief announcement but a full registration statement, supporting high confidence.
2019-03-08 English
10-K
Annual Report FY 2018
2019-03-08 English
8-K
Earnings Release Classification · 90% confidence The document is a Form 8-K filed with the SEC, dated March 8, 2019, reporting a corporate update and financial results for the fourth quarter and year ended December 31, 2018. The text states that the financial results are provided in a press release attached as Exhibit 99.1 and incorporated by reference. The document itself does not contain detailed financial statements or substantive financial data but rather announces the results and provides a link to the press release. The length of the document is 3362 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement of financial results, not the full earnings release itself. Therefore, the document should be classified as an Earnings Release (ER) because it announces quarterly/year-end financial results, but since the actual detailed results are in the attached press release, and the 8-K is the initial announcement, ER is the best fit here.
2019-03-08 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.